It was first approved in the United States in 2014 and is not a GLP-1 medicine.1
What it is
Each extended-release tablet holds 8 mg of naltrexone hydrochloride and 90 mg of bupropion hydrochloride. On its own, bupropion is used to treat depression and to help people stop smoking, and naltrexone to help people who have stopped drinking or using opioids control cravings.2,3 Because Contrave contains bupropion, it carries the boxed warning that antidepressants share. It describes a higher risk of suicidal thoughts and behavior in children, teenagers and young adults taking antidepressants, and asks for monitoring for worsening mood or new suicidal thoughts.1
How the dose climbs
Contrave is taken by mouth, swallowed whole, and climbs over three weeks to two tablets twice a day.1
| Week | Morning | Evening |
|---|---|---|
| 1 | 1 tablet | None |
| 2 | 1 tablet | 1 tablet |
| 3 | 2 tablets | 1 tablet |
| 4 onward | 2 tablets | 2 tablets |
CONTRAVE prescribing information, Table 1.1
From week 4 the daily total is 32 mg of naltrexone and 360 mg of bupropion. The label sets a check: after 12 weeks at that maintenance dose, an adult who has not lost at least 5% of starting weight should stop, because meaningful weight loss is then unlikely with more treatment.1 Counting the three weeks of the climb, that check falls at about week 16.
What it did in trials
Three 56-week trials support the approval.1
- COR-I, with standard diet and exercise advice: weight fell by 5.4% on Contrave against 1.3% on placebo. At least 5% was lost by 42% against 17%, and at least 10% by 21% against 7%.
- COR-BMOD, with an intensive behavior program: 8.1% against 4.9%.
- COR-Diabetes, in adults with type 2 diabetes: 3.7% against 1.7%.
Those losses are smaller than in the trials of the weekly GLP-1 medicines, such as 14.9% on Wegovy over 68 weeks, though no trial put the two against each other.4 The difference in mechanism also matters. GLP-1 medicines act on gut hormone receptors; Contrave acts on the brain through an opioid blocker and an antidepressant, so it suits different people and raises different safety questions.
Side effects and who should not take it
In the label's trials, nausea was reported by 32.5% on Contrave against 6.7% on placebo, constipation by 19.2% against 7.2% and headache by 17.6% against 10.4%. Vomiting was reported by 10.7% against 2.9%, dizziness by 9.9% against 3.4% and insomnia by 9.2% against 5.9%.1
The label rules Contrave out for people with uncontrolled high blood pressure, a seizure disorder or past seizures, bulimia or anorexia nervosa, or long-term use of opioids such as methadone or buprenorphine. It also rules it out alongside other bupropion products and during an abrupt stop of alcohol or benzodiazepines.1 Because naltrexone blocks opioids, the label warns that opioid painkillers, cough remedies and antidiarrheals may not work fully, and that trying to overcome the block with large opioid doses can cause a fatal overdose.1
Contrave in eight lines
| Fact | Contrave |
|---|---|
| Active ingredients | Naltrexone and bupropion |
| First U.S. approval | 2014 |
| Form | Extended-release tablet |
| Full dose | 2 tablets twice a day, from week 4 |
| Stop rule | Under 5% lost after 12 weeks at full dose |
| Boxed warning | Suicidal thoughts and behaviors |
| Is it a GLP-1 | No |
| Approved for | Weight, in adults |
CONTRAVE prescribing information, DailyMed version of November 17, 2025.1
Related terms
Qsymia is the other combination tablet for weight, built from phentermine and topiramate. Our page on GLP-1 costs without insurance lists self-pay prices of the injections and tablets, and alcohol on a GLP-1 covers the research on GLP-1 medicines and drinking.
Sources
- CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. DailyMed, U.S. National Library of Medicine, version published November 17, 2025; boxed warning and sections 1, 2, 4, 5, 6.1, 7.2 and 14. dailymed.nlm.nih.gov
- MedlinePlus. Naltrexone. U.S. National Library of Medicine; last revised September 15, 2026, read November 20, 2026. medlineplus.gov
- MedlinePlus. Bupropion. U.S. National Library of Medicine; last revised November 15, 2025, read November 20, 2026. medlineplus.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
Related analyses
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Alcohol on a GLP-1: what the labels say, what counts as a drink, and what five studies found
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Wegovy weight loss chart: the trial results week by week, in your own weight
Log each tablet and your weight, and see week 16 coming.
Open Dose Insider